Fisher & Paykel Healthcare (ASX FPH) is a High Growth Medical Ventilator Provider Leveraged To COVID-19

Fisher and Paykel Healthcare (ASX FPH)

Henry Fung

Henry is a co-founder of MF & Co. Asset Management with over 15 years of experience as a trader, investor and asset manager. Henry runs the Options Income Strategy and has a free 5-day options income strategy course you can take to learn how to use options to generate income.

May 27, 2020

Today we’ll look at why we like Fisher & Paykel Healthcare (ASX FPH).

We first looked at this stock back in May 2019, when the stock was at $14.50.

As of writing, the FPH share price is at $28.66 or 98% higher since we first looked at the stock.

The rally in the stock started in August 2019, well before COVID-19 became an issue. This is likely due to its strong revenue growth since then.

Considering that FPH specialises in the manufacture of medical ventilators, the need for governments to hedge against the current and the next outbreak will likely see continual growth in revenue for this stock.

FPH is a world leader in medical ventilator manufacturing, whose consecutive profits in the last five years and accumulated profit reserves are sufficient to finance a rapid expansion to meet the drastically increased needs of ventilators due to COVID-19.

About Fisher & Paykel Healthcare Corporation Limited

Fisher & Paykel Healthcare Corporation Limited (ASX FPH) is a $16 billion company that produces medical equipment for use in respiratory care, acute care, surgery, and in the treatment of obstructive sleep apnoea.

FPH provides products and services to hospitals and home care by offering respiratory humidifiers, single and reusable chambers, breathing circuits, and accessories. These medical devices incorporate patented and other proprietary technologies.

Only 1% of revenue comes from New Zealand, its headquarters and its products are sold by around 120 countries worldwide.

FPH’s innovation in technology

In 2019 a leading US physician Professor indicated there is a potential benefit in treating chronic obstructive pulmonary disease (COPD) by using FPH’s Opti-flow and AIRVO systems.

FPH’s products can be categorised in hospital and home care products and the hospital-related products are most likely to see short-term escalated demand due to Covid-19.

FPH’s hospital product group constitutes 62% of total revenue, and it includes humidification products used in invasive and non-invasive ventilation, nasal high flow therapy, and open surgery.

You may also like...
Nanosonics (ASX:NAN) to Benefit from COVID Normalisation and Market Expansion

In the Pre-COVID period of FY19, the hospital product group saw a 19% revenue growth, and the current demand for ventilators is expected to boost sales in the hospital category.

On the other hand, FPH’s home care product, which contributes 38% of the total revenue, has seen favourable revenue growth in FY19, due to the launch of a new product.

In 2019 H1, FPH launched Vitera, a full-face mask for patients with obstructive sleep apnoea (OSA) in Australia, Europe, and Canada.

ASX FPH Revenue by Product

Source: Fisher & Paykel Healthcare annual report 2019

Clinical evidence in FPH’s products

ASX FPH clincal evidence FPH

ASX FPH Kaplan-Meier

Source: Fisher & Paykel Healthcare

FPH offers a cheaper yet more efficient therapy for COPD. As illustrated above, treatment with FPH’s NHF oxygen therapy reduced 90-day mortality and the need for intubation for acute patients compared with standard oxygen therapy.

FPH has thus established a dominant market share and a high-profile brand in the core hospital business in ICU, in the application of Nasal high flow (NHF) and Non-invasive ventilation (NIV).

FPH’s diversification in revenue

ASX FPH Revenue by Region

Source: Fisher & Paykel Healthcare annual report 2019

The company sells in more than 120 countries, and the North America region accounts for around 45% of annual revenues, followed by Europe (28%), Asia Pacific (22%) and others (5%).

FPH aims to increase the effectiveness and efficacy of treatment of COPD through its proprietary patented equipment such as Opti-flow and nasal high flow technology.

Its unconventional treatment has reduced costs, treatment intensity, and duration of hospital stay for patients.

Additionally, FPH is market-leading in the ICU sector with limited competition.

In the last five years, its applications consumables sales of NHF and NIV has grown at over 20% per annum and is currently making up 60% of hospital sales.

FPH also produces respiratory humidifiers and consumables that are essential to treating patients infected by Covid-19.

Financial Performance

FPH updated its revenue and profit guidance on 21/02/2020 due to the coronavirus pandemic.

You may also like...
Webjet (ASX:WEB) Well-Positioned to Leverage COVID Recovery In Travel

FPH’s revenue is showing a predictable upwards trend which will most likely accelerate thanks to COVID-19.

ASX FPH revenue GP ebitda NI NP


Source: Bloomberg

FPH’s net income surged 12.09% in 2019 to 200.3 million, due to improved profit margins.

The adjusted dividend and earning per share continues to improve, reaching 22% and 38.5% per share in FY19, respectively.

Consequently, FPH’s P/E was trending up steadily before seeing a spike around 03/2020 due to the coronavirus.

FPH to increase production to meet demand

FPH will ramp up production in Auckland and Mexico by putting on extra shifts and hiring more workers.

Along with respiratory humidifiers, FPH will make other medical consumables such as nasal cannulas and mask interfaces used in the treatment of COVID-19.

ASX FPH Foreign currency imp

Source: Fisher & Paykel Healthcare Annual report 2019

FPH generates over 99% of sales in foreign currencies and the company may face currencies mismatch as around 40-50% of the costs is incurred in NZD.

As illustrated, 50% of currency exposure came from U.S. dollars, followed by Euros (19%), Australian dollars and Japanese yen (6%), and other currencies (25%).

FPH’s strength in a post-COVID-19 world is that it takes advantage of the coronavirus pandemic while most industries shut down and downgrade their profit guidance.

We believe the impact of coronavirus is not entirely reflected in the FPH’s stock price yet, and the rising demand for medical equipment and a weakening NZD would contribute positively to FPH’s bottom lines.

Peer Analysis

ResMed (ASX RMD) is a manufacturer and distributor of medical equipment based in the US, a strong competitor of FPH.

ASX FPH Revenue Comparison

ResMed has higher revenue growth than FPH.

FPH saw an average of 13% of revenue growth, from $631M to $1026.7M, while ResMed managed 14.3% of average revenue growth, from $2186M to $3717M FY15-19.


ASX FPH - ResMed revenue GP ebitda NI NP

ASX FPH Ebitda ResMed

ResMed saw higher average revenue growth in FY15-FY19. FPH and ResMed both saw an upward trend in both revenue and gross profit but ResMed managed a slightly higher revenue growth, despite its higher volatility in profit margin.

FPH expects to see higher revenue growth than ResMed in FY20, as although ResMed produces ventilators, this category makes up less than 10% of its sales.

You may also like...
Magnis Energy Technologies (ASX:MNS) a Solid Long-Term Bet On The EV Boom

Industry analysis

Rapid growth in the global market of respiratory humidification



Source: Market Watch

COPD is the fourth leading cause of death in the United States. It is estimated that up to fifteen million US adults are diagnosed with COPD, and twelve million more COPD patients remain undetected in 2020.

COPD costs the U.S. about USD$30B in healthcare expenses per year, and this cost is expected to increase to $49 billion by 2020.

The global medical equipment market is expected to grow at 8.6% CAGR FY19-24, from USD$690M to USD$1130M.

Furthermore, the consumer price index for medical care services and commodities in the U.S is showing strong year on year growth.

This will contribute significantly to revenue growth for FPH.

ASX FPH consumer price index

Source: Statista

High-flow Nasal Cannula market is forecasted to grow at CAGR of 11.8% in 2020-2025.

The North American and Asia-Pacific HFN market shares are projected to be 43% and 17%, respectively.

ASX FPH High Flow Nasal Cannula Market Forecast

Source: High-flow Nasal Cannula Market Forecast

The efficiency of FPH’s solutions has decreased the need for invasive therapies, and thus the demand for FPH’s products has risen substantially.

In particular, the proven benefits of the AIRVO and Opti-flow system nasal high flow therapy for COPD patients are expected to drive higher sales growth in both the hospital and the homecare settings.


Fisher and Paykel Healthcare is a global leader in manufacturing medical devices related to sleep apnea, chronic obstructive pulmonary disease, and other respiratory conditions.

FPH aims to provide products both at home and in hospitals to relieve COPD symptoms and reduce medical costs for patients.

COPD is globally prevalent, and treatment in this field has high market potential.

Moreover, respiratory ventilators that FPH products are expected to see escalated growth in demand due to the COVID-19 pandemic.

With strong revenue growth and products that will likely see strong demand now and into the future, FPH is a stock that we like with strong potential upside.

Are you still looking for the best stocks to buy in 2021? We’ve put together a free report on 5 stocks that we think are the best buys on the ASX right now. Download it instantly here.

This is general advice only. MF & Co Asset Management has not considered your personal financial needs, objectives or current situation. This information is not an offer, solicitation, or a recommendation for any financial product unless expressly stated. You should seek professional investment advice before making any investment decision.

You May Also Like…


Want more Free Research?

Subscribe today for free and get an email with stocks to watch every Monday and new research every Thursday.

Invalid email address
We promise not to spam you. You can unsubscribe at any time.


What People are Saying...

See what people are saying about our research, products and services.

Nice reporting, thank you
Anthony David Critchley
Anthony David Critchley
09:25 23 Aug 21
Christophe Dussert
Christophe Dussert
07:16 23 Aug 21
Exceptional information that is concise and insightful. Keep up the great work !!!
09:19 19 Aug 21
I feel MF and Co are very informative with their advice and recommendations.
Norman Wilkins
Norman Wilkins
08:00 19 Aug 21
Good service with frequent emailed share suggestions.
Peter Farrell
Peter Farrell
03:39 19 Aug 21
Even I never trade with MF&Co, I watch all of Henry's review and analysis, very impressed with the accuracy and... objective of those thoughts.Of course no one can say what the future will be, but at least when reading those reviews, we know where we are, then sometimes that is the best thing that you can wish more
Vu Nguyen
Vu Nguyen
23:44 15 Aug 21
Excellent service, not pushy, clear reporting highly recommended
Luke Stewart
Luke Stewart
23:25 15 Aug 21
Some very useful research
Richard Goodwin
Richard Goodwin
04:33 13 Aug 21
I very much appreciate the profound stock market research and the peceived honesty.
Quentin Steinbeck
Quentin Steinbeck
16:10 11 Aug 21
Easy to understand research for “dummies guide to shares trading”
Graham Ko
Graham Ko
15:30 09 Aug 21
Easily some of the most worthwhile research presented without any bias.
Tony Miller
Tony Miller
01:06 07 Aug 21
Nice free report with a good stock pick tip. Thank you.
00:17 06 Aug 21
i subscribed to the free research report and i found it very informative and useful for making investing decisions. I’m... looking forward to meet advisers in person when lockdown eases to learn futures options trading and to join trading education courses. Thanks for providing company reports for gratis 🙏read more
Rahul Newar
Rahul Newar
13:37 05 Aug 21
Excellent…..highly recommend
12:05 05 Aug 21
Henry's website is an absolute Treasure of Insightful Financial AdviceFree, Honest & Profitable!
Jonathan Meader
Jonathan Meader
11:37 05 Aug 21
I follow every recommendation and they are always a winner.
Peter Logiotatos
Peter Logiotatos
08:37 05 Aug 21
Great info, has helped in choosing some quality stocks to invest in and have had great results from those investments.
Stuart Farnworth
Stuart Farnworth
07:54 05 Aug 21
You can rarely find relevant, dedicated, and most importantly, free research as good as the ones published here.
07:26 05 Aug 21
Excellent and balanced with great knowledge
Peter Cryan
Peter Cryan
06:53 02 Aug 21
Great research and useful information for current market situation and potential buys.
May Deng
May Deng
06:04 02 Aug 21
great knowledge base and excellent research.
colin blanch
colin blanch
00:56 02 Aug 21
I am registered only on the free advice, I have found their advice to be so much more complete compared to other sites... which you have to pay for, it is timely and does not seem to be a shotgun approach as many sites seem to do so that some time in the future they can cherry pick their good results. For me 1 or 2 shares a week is so much more meaning to me for my style of investment, do I recommend MF& co, I sure more
Phil O'Leary
Phil O'Leary
00:39 02 Aug 21
Ideas and complimentary assessments are informative, interesting and easy to read. They are sometimes 'out of box' in... thinking. To me, they install more
Grahame Cox
Grahame Cox
00:30 02 Aug 21
Informative information and well researched
David Bailey
David Bailey
00:12 02 Aug 21
Great research into current trends and foresight into what to watch for the future
00:03 02 Aug 21

MF & Co. Asset Management

MF & Co. Asset Management is a boutique investment firm offering Equity Capital Markets and derivative general advice & trade execution services.

We are specialists in advising and trading in Australian and US Equities, Index & Equity Options and Options on Futures.


Get In Touch

1300 889 603
+61 2 8378 7199
M-F: 8am-5pm

Suite 602, 37 Pitt St
Sydney, NSW 200


Share This